MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s40001-025-03219-6

Медицинская библиотека · European journal of medical research · 2025

TIGD6 in gastric cancer: exploring its prognostic value and therapeutic potential through molecular and clinical investigations.

Han Quanli, Deng Muhong, Cui Zhi, Wang Qi, Li Dongbing

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Gastric cancer (GC) predominantly contributes to cancer mortality, with adenocarcinomas accounting for more than 95% of incidences. Early detection improves survival, but most cases are diagnosed at advanced stages due to subtle symptoms and rapid progression. The role of TIGD6 in GC is unclear.

METHODS

We analyzed TIGD6 expression using TCGA data and correlated it with clinical features and outcomes in GC patients. Bioinformatics tools, including GSEA and single-cell sequencing, were used to elucidate TIGD6's role in GC. In the GC cell lines AGS and HGC-27, TIGD6 was knocked down using RNA interference, and subsequent in vitro experiments were conducted to evaluate cell proliferation, migration, and invasion capabilities.

RESULTS

The expression of TIGD6 was markedly elevated in GC tissues relative to normal tissues (p < 0.001). Higher TIGD6 levels were linked to residual tumors (p = 0.027), history of reflux (p = 0.019), and antireflux treatment (p = 0.0012). Increased TIGD6 expression was associated with decreased overall survival (OS, p = 0.009) and disease-specific survival (DSS, p = 0.008), and it served as an independent predictor of worse OS (p = 0.043). Knocking down TIGD6 in GC cells suppressed proliferation, migration, and invasion, while enhancing apoptosis through modulation of the Hedgehog signaling pathway.

CONCLUSION

TIGD6 is overexpressed in GC and linked to unfavorable outcomes. It could potentially function as a biomarker and therapeutic target for this malignancy. Future studies should validate its clinical relevance and explore its detailed molecular mechanisms. Collectively, this study provides the first functional, mechanistic, and immune-phenotypic characterization of TIGD6 in GC, positioning it as a dual biomarker and therapeutic target.

Для цитирования: Han Quanli, Deng Muhong, Cui Zhi, Wang Qi, Li Dongbing. TIGD6 in gastric cancer: exploring its prognostic value and therapeutic potential through molecular and clinical investigations.. European journal of medical research. 2025. DOI: 10.1186/s40001-025-03219-6.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.